GSK
GlaxoSmithKline PLC
50.50$
+0.3%
vs. previous close
Closing price · As of: Aug 13, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 27.2% | 44.9% | 16.2% | 14.1% | 26.9% | 28.7% | 15.2% | 26.2% | 35.4% | 23.6% | 15.0% | 30.2% | 26.3% | |
| 7.1% | 18.1% | 9.5% | 8.1% | 11.9% | 5.1% | 10.9% | 14.5% | 11.6% | 9.1% | 6.1% | 2.7% | 7.4% | |
| 3.8% | 3.8% | – | – | – | – | – | – | – | – | – | – | – | |
| -1.1% | – | – | – | – | – | – | – | – | – | – | – | – | |
| 2.0% | 22.6% | -5.4% | -7.8% | -9.2% | 46.3% | -10.5% | -12.9% | -12.5% | 16.1% | -14.2% | -0.1% | -2.3% | |
| 6.1% | 7.3% | 4.3% | 5.6% | 10.5% | 14.0% | 6.0% | 7.9% | 5.0% | 6.5% | 5.8% | 3.9% | 5.3% | |
| -6.0% | 3.6% | -3.5% | 9.8% | -9.1% | -13.8% | -15.2% | -7.8% | -25.2% | -27.4% | -19.2% | -10.5% | -20.7% | |
| 7.0% | 8.4% | 9.8% | 8.3% | 7.6% | 7.5% | 8.1% | 8.2% | 10.6% | 7.3% | 8.4% | 8.7% | 8.8% | |
| 0.1% | -0.6% | – | 0.0% | 0.2% | 0.2% | -3.3% | -7.0% | -5.2% | -15.8% | -4.3% | -3.7% | -7.4% | |
| -13.5% | – | – | – | -6.8% | 3.0% | 25.5% | -10.9% | -1.0% | 6.4% | 15.5% | -7.5% | 3.0% | |
| -21.6% | -50.5% | -17.0% | -20.1% | -15.5% | -10.4% | 11.4% | -29.7% | -20.0% | 9.4% | 3.6% | -22.6% | -7.6% | |
| -0.2% | -1.7% | -3.0% | 3.7% | 1.9% | 4.6% | 11.3% | -11.6% | -5.8% | 1.1% | -0.7% | -3.7% | -2.3% | |
| 21.1% | 37.6% | 11.9% | 8.5% | 16.4% | 14.7% | 9.3% | 18.3% | 30.4% | 17.1% | 9.1% | 26.2% | 21.0% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.